September 29, 2023
Hemogenyx Pharmaceuticals encouraged by the FDA’s response to plans to resolve a setback
Hemogenyx Pharmaceuticals, the Standard Listed biopharmaceutical group developing therapies designed to transform blood disease treatment, committed to progressing HEMO CAR-T to clinical trials as the its next step.